Omeros Corp. (OMER) announced positive results from its Phase 2 clinical trial of OMS721, for the treatment of thrombotic microangiopathies, Tuesday morning.
Omeros has gapped open sharply higher Tuesday and is now up 9.88 at $24.45 on the highest volume in 5 1/2 months. The stock has jumped to a 3 1/2 month high and has re-crossed is 50 and 200-day moving averages.
For comments and feedback contact: editorial@rttnews.com
Business News